Evaluation and treatment of malignant ascites secondary to gastric cancer

doi:10.3748/wjg.v21.i39.10936

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 39

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12818)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

898

WORD

238

HTML

7296

Figures (1-2)

135

Tables (1-3)

148

Sum=8715

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

556

Download

1115

Sum=1671

Publishing Process of This Article

Item

Count

Browse

1030

Download

1402

Sum=2432

Oct 21, 2015 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (57)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Oct 21, 2015; 21(39): 10936-10947
Published online Oct 21, 2015. doi: 10.3748/wjg.v21.i39.10936

Table 2 Factors influencing development of ascites due to gastric cancer[19-26]

Increased fluid production

Increased vascular permeability due to increased VEGF and/or MMP-2/-9

Neovascularization of peritoneum

Peritoneal inflammation

Increased portal pressure due to tumor metastasis

High protein concentrations in ascites

Lower concentration of serum proteins due to undernutrition

Decreased drainage of peritoneal fluid

Obstruction of lymphatics

MMP: Matrix metalloproteinase; VEGF: Vascular endothelial growth factor.

Citation: Maeda H, Kobayashi M, Sakamoto J. Evaluation and treatment of malignant ascites secondary to gastric cancer. World J Gastroenterol 2015; 21(39): 10936-10947
URL: https://www.wjgnet.com/1007-9327/full/v21/i39/10936.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i39.10936